EA200800343A1 - Ингибиторы jnk для лечения эндометриоза - Google Patents

Ингибиторы jnk для лечения эндометриоза

Info

Publication number
EA200800343A1
EA200800343A1 EA200800343A EA200800343A EA200800343A1 EA 200800343 A1 EA200800343 A1 EA 200800343A1 EA 200800343 A EA200800343 A EA 200800343A EA 200800343 A EA200800343 A EA 200800343A EA 200800343 A1 EA200800343 A1 EA 200800343A1
Authority
EA
Eurasian Patent Office
Prior art keywords
endometriosis
treatment
jnk inhibitors
relates
jnk inhibitor
Prior art date
Application number
EA200800343A
Other languages
English (en)
Other versions
EA016437B1 (ru
Inventor
Стефен С. Палмер
Селварадж Натараджа
Original Assignee
Лаборатуар Сероно С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Сероно С.А. filed Critical Лаборатуар Сероно С.А.
Publication of EA200800343A1 publication Critical patent/EA200800343A1/ru
Publication of EA016437B1 publication Critical patent/EA016437B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к способу лечения и/или профилактики эндометриоза, включающему введение ингибитора JNK. Ингибитор JNK также может быть введен в комбинации с гормональным супрессором. Изобретение также относится к лечению связанного с эндометриозом бесплодия.
EA200800343A 2005-07-15 2006-07-12 Ингибитор jnk для лечения эндометриоза и содержащая его фармацевтическая композиция EA016437B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69965805P 2005-07-15 2005-07-15
EP05109447 2005-10-11
PCT/US2006/027455 WO2007011762A2 (en) 2005-07-15 2006-07-12 Jnk inhibitors for the treatment of endometreosis

Publications (2)

Publication Number Publication Date
EA200800343A1 true EA200800343A1 (ru) 2008-06-30
EA016437B1 EA016437B1 (ru) 2012-05-30

Family

ID=35709133

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800343A EA016437B1 (ru) 2005-07-15 2006-07-12 Ингибитор jnk для лечения эндометриоза и содержащая его фармацевтическая композиция

Country Status (11)

Country Link
US (1) US8592414B2 (ru)
EP (1) EP1904181A2 (ru)
JP (1) JP2009509916A (ru)
KR (1) KR20130087052A (ru)
AU (1) AU2006270184B2 (ru)
BR (1) BRPI0613042A2 (ru)
CA (1) CA2611598A1 (ru)
EA (1) EA016437B1 (ru)
MX (1) MX2008000663A (ru)
SG (1) SG165343A1 (ru)
WO (1) WO2007011762A2 (ru)

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
ATE190461T1 (de) 1983-11-02 2000-04-15 Applied Research Systems Produkte und methoden für die herstellung einer heterodimerer menschlicher lh mit einem met42 val55 alpha untereinheit
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US4988679A (en) 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JP2864434B2 (ja) 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
US5433951A (en) 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
DE59509577D1 (de) 1995-02-16 2001-10-11 Merck Patent Gmbh Vinylenverbindungen und flüssigkristallines Medium
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
KR20010101266A (ko) 1998-12-17 2001-11-14 프리돌린 클라우스너, 롤란드 비. 보레르 Ｊｎｋ 단백질 키나제의 억제제로서의 4-아릴옥신돌
TR200101747T2 (tr) 1998-12-17 2001-11-21 F.Hoffmann-La Roche Ag 4- ve 5-alkinil oksindoller ve 4- ve 5-alkeniloksindoller.
CN1159315C (zh) 1998-12-17 2004-07-28 霍夫曼-拉罗奇有限公司 4,5-吡咯并羟吲哚
ATE425142T1 (de) 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
AU6909600A (en) 1999-08-13 2001-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1218347A1 (en) 1999-08-19 2002-07-03 Signal Pharmaceuticals, Inc. Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
US20020115689A1 (en) 1999-12-21 2002-08-22 Joanne Waldstreicher Combination therapy for treating neurodegenerative disease
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
JP2003531580A (ja) * 2000-02-25 2003-10-28 メトリオジェーン・バイオサイエンシイズ・インコーポレイテッド 子宮内膜症関連マーカー及びその使用
EP1193267A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
WO2003047570A1 (en) 2001-12-07 2003-06-12 Applied Research Systems Ars Holding N.V. Benzazole derivatives for the treatment of scleroderma
JP2005525096A (ja) * 2002-01-09 2005-08-25 ユニバーシティ オブ ローザンヌ Ｊｎｋシグナル伝達経路の細胞浸透性ペプチドインヒビター
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
AU2003217961B2 (en) * 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
IL164796A (en) * 2002-04-25 2013-02-28 Pascale Gailllard Piperazine benzothiazole derivatives, their preparation, pharmaceutical compositions containing them and their use
CN1684583A (zh) 2002-09-25 2005-10-19 明治制果株式会社 缓释农药颗粒剂
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
WO2004082665A1 (ja) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 放出制御組成物
PT1696909E (pt) 2003-09-12 2007-12-21 Serono Lab Derivados benzotiazolo para o tratamento de diabetes
JP5037944B2 (ja) 2003-10-30 2012-10-03 メルク セローノ ソシエテ アノニム 液状又はペースト状物質を冷却し霧化する方法と装置
RU2253489C1 (ru) * 2004-04-07 2005-06-10 Научный центр акушерства, гинекологии и перинатологии РАМН Способ лечения бесплодия у женщин с наружным генитальным эндометриозом
DE602005010604D1 (de) * 2004-11-17 2008-12-04 Ares Trading Sa Benzothiazolformulierungen und ihre verwendung
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof

Also Published As

Publication number Publication date
EP1904181A2 (en) 2008-04-02
KR20130087052A (ko) 2013-08-05
AU2006270184B2 (en) 2011-09-29
US8592414B2 (en) 2013-11-26
AU2006270184A1 (en) 2007-01-25
JP2009509916A (ja) 2009-03-12
EA016437B1 (ru) 2012-05-30
BRPI0613042A2 (pt) 2010-12-14
WO2007011762A8 (en) 2007-08-02
MX2008000663A (es) 2008-03-13
WO2007011762A3 (en) 2007-04-05
SG165343A1 (en) 2010-10-28
US20090176761A1 (en) 2009-07-09
WO2007011762A2 (en) 2007-01-25
CA2611598A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
WO2006099261A3 (en) Potent and specific immunoproteasome inhibitors
SG157365A1 (en) Compositions and methods for treating neoplastic diseases
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
EA200870425A1 (ru) Применение агонистов рецептора grp119 для повышения костной массы и для лечения остеопороза и связанной с ними комбинированной терапии
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
JO3358B1 (ar) معالجات حساسية العيون
EA201100609A1 (ru) Способы лечения воспаления
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
NO20065297L (no) Anvendelse av GPCR54 ligander til behandling av infertilitet
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
NO20065859L (no) Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
UA96736C2 (ru) Ингибиторы pi3k для лечения эндометриоза

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU